Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

News Conference News TCT 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

Yael L. Maxwell

October 26, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

News Conference News THT 2023

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

March 21, 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

March 10, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

May 02, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 07, 2022

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.